Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects - Reuters

1. Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects  Reuters
2. Novo hunts for ‘maximum potential’ from obesity drug CagriSema  Financial Times
3. Novo Nordisk’s amylin obesity drug keeps performing like Zepbound  STAT
4. Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses  Bloomberg.com
5. CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM  Yahoo Finance

from Top stories - Google News https://ift.tt/MEOrsAk